Summary Amplification and overexpression of the erbB-2 oncogene is an unfavourable prognostic marker in human breast cancer and occurs in approximately 25% of breast carcinomas. We used erbB-2 antisense oligonucleotides to inhibit the proliferation of human breast cancer cell lines. erbB-2 antisense oligonucleotides (20 JLM) inhibited the growth and DNA synthesis of breast cancer cell lines with an amplified erbB-2 gene by up to 60%. Control complementary sense oligonucleotides did not inhibit cellular proliferation at the same concentration but showed inhibitory effects at higher concentrations. There was no specific effect of erbB-2 antisense oligonucleotides on breast cancer cell lines that had no amplification of erbB-2. erbB-2 antisense oligonucleotides reduced erbB-2 protein levels, measured by immunohistochemistry, in a dose-dependent manner. erbB-2 sense oligonucleotides did not decrease the levels of erbB-2 protein. These data indicate that erbB-2 antisense oligonucleotides induce a specific inhibition of erbB-2 protein expression and that erbB-2 gene overexpression is important for the proliferation of the breast cancer cells that have been selected for erbB-2 amplification.
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The erbB-2 oncogene (also called neu and HER-2) codes for a 185 kDa transmembrane growth factor receptor with an intracellular tyrosine kinase catalytic domain (Schechter et al., 1985; Coussens et al.. 1985; Yamamoto et al., 1986) . The erbB-2 gene copy number is amplified in many adenocarcinomas and, in particular, erbB-2 is amplified or overexpressed in approximately 25% of human breast carcinoma samples (Maguire & Greene, 1989) . Overexpression of erbB-2 has not been observed in normal adult human tissues . Amplification or overexpression of erbB-2 in malignant breast tumours has been correlated with nodal metastases, early relapse and shortened survival (Slamon et al., 1987; Tandon et al.. 1989; Wright et al., 1989; Paik et al.. 1990) . Moreover, expression of high levels of erbB-2 oncogene is sufficient to induce neoplastic transformation of some cell lines (DiFiore et al., 1987; Hudziak et al.. 1987; Tarakhovsky et al., 1990) . A role for erbB-2 in the aetiology of some breast carcinomas was further suggested by transgenic mouse experiments. in which animals expressing the erbB-2 gene under the control of a steroid-inducible promoter manifested a breast adenocarcinoma phenotype (Muller et al., 1988; Bouchard et al., 1989) .
It has been shown that monoclonal antibodies against the erbB-2 oncoprotein applied to cells transformed by the rat neu oncogene cause them to revert to a non-transformed phenotype (Drebin et al., 1985; van Leeuwen et al., 1990) , and these antibodies diminished the in vivo tumorigenicity of transplanted murine fibroblasts transformed by neu (Drebin et al., 1986 (Drebin et al., , 1988 . In addition, monoclonal antibodies to the human erbB-2 protein also inhibited the in vitro growth of the erbB-2-overexpressing human breast cancer cells SK-Br-3 by 56% (Hudziak et al., 1989) . The antiproliferative effects of the erbB-2 antibodies are related to their ability to downregulate the erbB-2 protein. While erbB-2 antibodies which reduce the levels of erbB-2 exhibit antiproliferative effects, monovalent F(ab) fragments (Drebin et al., 1986; Kumar et al., 1991; Sarup et al., 1991) Tidd, 1990; Uhlmann & Peyman, 1990 : Carter & Lemoine, 1993 . Antisense oligonucleotides have been used to study the in vitro cellular effects of oncogenes and growth factors in cells from leukaemia (Holt et al., 1988; Wickstrom et al., 1988; Reed et al.. 1990; Szcyzylik et al., 1991) , lymphoma (McManaway et al., 1990) and solid cancers (Rosolen et al., 1990; Melani et al., 1991; Morrison, 1991; Saison-Behmoaras et al., 1991) .
We report the effect of erbB-2 antisense oligonucleotides on cell proliferation and erbB-2 protein expression in breast cancer cells. The results show that the proliferation of human breast cancer cells -measured by cell growth and DNA synthesis -can be inhibited following treatment with antisense oligonucleotides and that this effect is specific for breast cancer cells which present erbB-2 amplification. In addition, expression of the erbB-2 oncogene product in breast cancer cells is reduced in a dose-dependent fashion by erbB-2 antisense, but not sense, oligonucleotides, indicating that overexpression of erbB-2 is important for the proliferation of those cells that have been selected for erbB-2 gene amplification.
Materials and metbods

Oligonucleotides
Oligonucleotides were synthesised on a Milligen/Biosearch DNA Cyclone by means of phosphoramidite chemistry. The lyophilised product was dissolved in TE buffer (1O mM Tris Cl, I mM EDTA, pH 7.4) and stored at -20°C. We selected sequences from the 5' end of the erbB-2 gene and performed a computer search in the GenBank database to obtain information about other possible sequence matches. For our experiments we chose a 21-nucleotide sequence directed against the 5'-translated end of erbB-2 that showed no sequence matches against the database, and a partially overlapping 15-mer that also included the erbB-2 initiation codon and had imperfect matches to human crystallin and keratin K7 genes. Their complementary sense sequences were used as controls. The oligonucleotide sequences are as follows: 1, 1 5-mer antisense, GGC CGC CAG CTC CAT; 2, 1 5-mer sense, ATG GAG CTG CGC GCC; 3, 21-mer antisense, GCG GCA CAA GGC CGC CAG CTC; 4, 21-mer sense, GAG CTG GCG GCC TTG TGC CGC. In some experiments, a 21-mer was synthesised with the same overall oligonucleotides content as 3, but with a random order (nonsense 2 1 -mer). (Biofluids) .
To assay the stability of oligonucleotides in media over time, oligonucleotides were added to IMEM containing 5% FCS or serum-free medium and incubated at 3TC. Samples of 0.4 ml of medium were aliquoted at specified times, phenol extracted, ethanol precipitated, and run on a 20% polyacrylamide gel. Seventy micrograms of a 20-mer oligonucleotide was incubated with 2.8 ml of serum-containing medium at 37C. Twenty-five micrograms of a 21-mer was incubated with 2 ml of serum-free medium.
Uptake offluoresceinated oligonucleotides For oligonucleotide uptake experiments, aminolinker-derivatised oligonucleotides were synthesised on an Applied Biosystems 381A DNA synthesiser. Oligonucleotides were incubated with a fluorescein isothiocyanate (FITC) sodium carbonate/sodium bicarbonate -water -dimethylformamide (5:8:2) solution overnight in the dark. The reaction mixture was passed through a Sephadex G50 column to remove excess FITC, eluting with 20% ethanol in water. The fractions selected showed simultaneous absorption at 260 nm (DNA) and 500 nm (FITC).
To analyse cellular fluorescence, cells were plated in sixwell plates at a concentration of 106 cells per well and allowed to attach overnight. Medium was then changed to serum-free medium containing 50 LM fluorescein-labelled oligonucleotides, and incubated overnight. After washing the wells with phosphate-buffered saline (PBS) cells were detached with PBS-EDTA, and cellular fluorescence was quantitated using a fluorescence-activated cell sorter (FACStar Plus). To assess whether the fluorescence assessed by FACS was intracellular, we used fluorescence microscopy. Cells were plated in eight-well Lab-Tek chamber slides (Miles Labs, Naperville, IL, USA) at a concentration of 10,000 cells per well and allowed to attach overnight. Medium (Table I) . We used fluorescence microscopy to study the pattern of cellular staining that resulted in our experiments with labelled oligonucleotides. After exposure cells to FITC-labelled oligonucleotides, the location of the fluorescent label was predominantly intracellular.
Inhibition of cell proliferation
The effect of erbB-2 antisense oligonucleotides on breast cancer cell growth was tested by cell proliferation assays, (Figure lb) . BT-474 cells treated for 7 days with 20 pM erbB-2 antisense oligonucleotides increased cell number by a factor of 1.1, while cells treated with the same concentration of sense oligonucleotide underwent a 2.5-fold increase. erbB-2 antisense oligonucleotide concentrations of 100 JM induced a 30% inhibition of growth in the lines MDA-MB-453 and MDA-MB-361, which also have amplification of erbB-2, but there was no apparent inhibitory effect on these cell lines by the sense strand oligonucleotides at 100 IM oligonucleotide concentrations. Since uptake of oligonucleotide was similar in all the cell lines tested, differences in cell line sensitivity to erbB-2 antisense oligonucleotides may be due to variation in the growth dependance of a particular cell on the erbB-2 oncogene signal.
We used MDA-MB-468 and MCF-7 cell lines, which do not have erbB-2 amplification, as controls to study the specificity of the effects of erbB-2 antisense oligonucleotides on cultured breast cancer cells. MDA-MB-468 cells have undetectable levels of erbB-2 and overexpress the epidermal growth factor receptor gene. MCF-7 cells have low levels of erbB-2, as assessed by flow cytometry. Both cell lines were shown to have an uptake of FITC-labelled oligonucleotide similar to the cell lines with erbB-2 amplification (Table I) .
We observed no differences in cell growth of MDA-MB-468 cells when antisense and sense erbB-2 oligonucleotide treatments were compared (Figure lc) . Dose-related nonspecific toxicity was seen in this cell line to the degree that cell growth was inhibited 20% at 100 jM of either sense and antisense oligonucleotides. Similarly, no sequence-specific effects of erbB-2 antisense oligonucleotides were observed in MCF-7 cells.
To examine whether the antiproliferative effects of erbB-2 antisense oligonucleotides were reflected by changes in cellular DNA synthesis, we assayed short-term incorporation of [3Hjthymidine into DNA after exposure to 1 5-mer oligonucleotides. As shown in Figure 2 , thymidine incorporation into DNA was inhibited in SK-Br-3 cells by the erbB-2 antisense oligonucleotides in a dose-dependent manner. The control sense strand had no effect on DNA synthesis at concentrations up to 10iM, but caused non-specific inhibition of thymidine incorporation at 40 ILM, which was consistent with the oligonucleotides toxicity threshold for SK-Br-3 cell growth. Differences in [3HJthymidine incorporation were not due to competition of free thymidine resulting from oligonucleotides degradation, since the number of thymidine residues in both the sense and antisense 1 5-mer erbB-2 10 000' na thymidine incorporation experiment was done over a time course of 4 h and cell number in the growth experiment was counted after 7 days, these two results cannot be compared directly. The efficacy of the oligonucleotides in culture may diminish over 7 days even though we could not demonstrate appreciable degradation in serum-free medium.
Inhibition of erbB-2 protein expression The effect of erbB-2 antisense oligonucleotides on cellular erbB-2 protein expression was assessed immunohistochemically and quantitated using an computerised image analysis system. Breast cancer cells with erbB-2 amplification were incubated for 6 days with 21-mer erbB-2 oligonucleotides. erbB-2 staining can be observed in Figure 3 . with 20 gM erbB-2 antisense oligonucleotides was approximately 66% that of untreated cells (Table II (Figure 3 and data not shown). We were unable to explain this non-specific effect, which did not correlate with oligonucleotide concentration. However, the apparent enhancement of the staining reaction by oligonucleotides suggests that the magnitude of the inhibitory effect of antisense oligonucleotides may be an underesimate of the actual effect.
Our experiments provide evidence that erbB-2 overexpression is important for the in vitro proliferation of human breast carcinoma cell lines derived from tumours with an amplfied erbB-2 gene. The decrease in erbB-2 protein levels induced by erbB-2 antisense oligonucleotides significntly reduced cellular growth and thymidin incorporation into DNA of these breast cancer cell lines. This antiproliferative effect was specific, sine control oligonucleotides, which did not reduce erbB-2 protein levels, had no effect on cellular growth or DNA synthesis. The specificity of the effect of erbB-2 antisense oligonucleotides was fiuther demonstrated by their lack of effect on MDA-MB-468 and MCF-7 cels, which do not express or express low levels of erbB-2. erbB-2 antisense oligonucleotides did not arrest completely the growth of the cells overexpressng erbB-2. In our experiments we observed a maximum of 60% inhibiton of growth.
We geerally treated our cultures once with oligonuclotides and measured growth at 7 days. Since intracellular degradation of oligonucleotides occurs, a daily treatment may have achieved a greater degree of cell growth inhibition. Furthermore, the cell lines used in these experiments contained other genetic alterations in addition to erbB-2 amplification, which also may drive cell growth independent of erbB-2. For example, SK-Br-3 cells express c-fins and CSF-I and have an amplification of the c-myc gene (Horiguchi et al., 1988) .
MDA-MB-453 and MDA-MB-361 ells overexpress erbB-3 (Kraus et al., 1989; Plowman et al., 1990 erbB-2 staining (data not shown). erbB-2 antisense oligonucleotides decreased the levels of erbB-2 protein in the cell membrane without a concurrent increase in intracellular stain, which is consistent with a decreased erbB-2 protein synthesis. This contrasts with the down-regulating effect of the erbB-2 ligand gp3O on cells overexpressng erbB-2. gp3O decreases membrane-associated erbB-2, but partly at the expense of increased intracellular accumulation of erbB-2 protein (Bacus et al., 1992) .
By inhibiting the expression of erbB-2 protein with antisense oligonucleotides we have shown that breast cancer cells with erbB-2 amplifction are subject to specific growth inhibition. Our results support the hypothesis that erbB-2 oncogene amplification confers a growth advantage on cells (DiFiore et al., 1987; Hudziak et al., 1987) . Other procedures that decrease erbB-2 levels interfere with cellular proliferation. The selective pressure provided by very high erbB-2 receptor levels can be reversed using monoclonal antibodies to erbB-2 (Drebin et al., 1988; Hudziak et al., 1989) . In addition, we have reported that elevated concentrations of gp3O are growth inlhibtory in cells with elevated expression of erbB-2 (Lupu et al., 1990) . Clinically, erbB-2 is overexpressed in 25% of human primary breast carcinomas, and it is correlated with an adverse prognosis. The experimental data strongly suggest that the erbB-2 oncogene and its product can be potential therapeutic targets in a signiiant fraction of breast carcinomas. Therapeutic strategies aimed at the erbB-2 gene may have a relatively high therapeutic index. We make this speculation based on the fact that two cancer cell lines without erbB-2 overexpression showed no growth effects after erbB-2 antisense oligonucleotides treatment and, similarly erbB-2 antibodies and gp30 had no antiproliferative effects on cells without overexpression (Hudziak et al., 1989; Lupa et al., 1990) . This theoretical approach is further supported by the observations that there is homogeneous overexpression of erbB-2 among the cancer cells in breast tumours that overexpress the oncogene (Iglehart et al., 1990) , while the surrounding mammary tissue is essentially void of erbB-2 overexpression, as are other normal tissues throughout the body . Antisnse oligonucleotides chemical analogues synthesisd to confer relative serum and cellular nuclease resistance represent a new class of compounds with potential appUlcation for gene-specific therapeutic intervention (Tidd, 1990) . Experiments with these agents n vivo will help define the spectrum of applications for oligonucleotides and their derivatives.
